Robert Stein

Professor of Breast Oncology

University College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Robert Stein is a Professor of Breast Oncology at University College London, United Kingdom. His research primarily focuses on neoadjuvant chemotherapy strategies for operable breast cancer, personalized treatment approaches, and the molecular mechanisms underlying breast cancer progression. Recent publications include studies on gene expression in tumor characterization and the impact of healthcare communication on patient trial participation.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2020

Collaborators (3)

Janet Dunn

Professor of Clinical Trials and Head of Cancer trials

University of Warwick

UNITED KINGDOM

View details

Helena Earl

Professor Emeritus of Clinical Cancer Medicine

University of Cambridge

UNITED KINGDOM

View details

Clarinde Esculier

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robert Stein

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Abstract RF3-07: ROSCO: Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: Randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil,Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy

190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study

Multistate Gene Cluster Switches Determine the Adaptive Mitochondrial and Metabolic Landscape of Breast Cancer

Abstract PO4-16-02: Can high progesterone receptor (PgR) expression identify tumours with low-risk tumour gene expression scores?

Abstract 7559: Multi-state gene cluster switches determining the adaptive mitochondrial and metabolic landscape of breast cancer

Multistate Gene Cluster Switches Determine the Adaptive Mitochondrial and Metabolic Landscape of Breast Cancer

The role of healthcare professionals’ communication in trial participation decisions: a qualitative investigation of recruitment consultations and patient interviews across three RCTs

Abstract OT3-32-01: OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial

Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.

Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training

Collaborators (3)

Janet Dunn

Helena Earl

Clarinde Esculier

Make your next move.

Robert Stein

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Abstract RF3-07: ROSCO: Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: Randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil,Epirubicin &amp; Cyclophosphamide vs Docetaxel &amp; Cyclophosphamide chemotherapy

190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study

Multistate Gene Cluster Switches Determine the Adaptive Mitochondrial and Metabolic Landscape of Breast Cancer

Abstract PO4-16-02: Can high progesterone receptor (PgR) expression identify tumours with low-risk tumour gene expression scores?

Abstract 7559: Multi-state gene cluster switches determining the adaptive mitochondrial and metabolic landscape of breast cancer

Multistate Gene Cluster Switches Determine the Adaptive Mitochondrial and Metabolic Landscape of Breast Cancer

The role of healthcare professionals’ communication in trial participation decisions: a qualitative investigation of recruitment consultations and patient interviews across three RCTs

Abstract OT3-32-01: OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial

Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.

Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training

Collaborators (3)

Janet Dunn

Helena Earl

Clarinde Esculier

Make your next move.

Abstract RF3-07: ROSCO: Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: Randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil,Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy